Our findings show that although no mutations in p110δ have been detected thus far in breast cancer, the expression levels of p110δ are gradually increased during human breast cancer progression from grade I to grade III indicating that PI3K p110δ might play a prominent role in human breast cancer. This evidence concerns the gene PIK3CD and breast cancer.